Kidney cancer patients are now likely to get access to Bristol-Myers Sqiubb's immunotherapy on the NHS in England and Wales after all, as cost regulators have a change of heart and recommended the drug.
Patients with severe plaque psoriasis living in England and Wales should now get access to Celgene's Otezla on the NHS like their counterparts in Scotland, after cost regulators concluded that the drug is a cost-effective use of resources.
Cost regulators for the NHS in England and Wales are backing use of a new therapy to treat the rare genetic disorder Fabry disease with a price tag of £210,000 per patient per year (excluding VAT and any discounts).
New controls to curb the National Health Service's agency staff bills have saved £600 million in the first year of their introduction, but spending is still too high, says health service regulator NHS Improvement.
PTC Therapeutics has been denied its first appeal contesting US regulators' refusal to accept its marketing application for Translarna as a treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).